OptumRx and CVS Pharmacy Partner to Expand Consumer Choice, Reduce Costs and Improve Health Outcomes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
UBS Raises Price Target on UnitedHealth Group (UNH) Following Investor Day
November 30, 2016 9:49 AM ESTUBS reiterated a Buy rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $193.00 (from $180.00), following the company's investor day. UNH expects its Medicare Advantage enrollment to grow by 700-800K lives in 2017, a 19-22% Y/Y increase. UBS raised 2016 EPS estimates to $9.45 and... More
Leerink Partners Raises Price Target on UnitedHealth Group (UNH) to $195; Reiterates Outperform
November 30, 2016 7:46 AM ESTLeerink Partners reiterated an Outperform rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $195.00 (from $185.00), following a company update. EPS guidance of $9.30 - $9.60 came in better than the Street expectation of $9.16. The EPS upside is driven by better than expected top-line growth in MA, and Optum as well as the ObamaCare tax holiday.
Analyst Ana Gupte, commented, "We remain bullish on UNH (OP) and reiterate our top pick status on the name while raising estimates and PT to $195. In addition to surprising meaningfully to the upside on 2017 guidance,... More
CVS's (CVS) OptumRx Win Belies Risk - Evercore ISI
November 29, 2016 10:01 AM ESTEvercore ISI analyst Ross Muken was positive on CVS Health (NYSE: CVS) after the company OptumRx (UNH) announced that they will offer the ability for OptumRx customers to fill 90-day prescriptions at either CVS retail pharmacies or via OptumRx home delivery. Additionally, the companies will offer improved consumer engagement tools and provide a shared pharmacy... More
